Bharat Parenterals Ltd Reports 19.8% Revenue Growth in FY25, Despite Consolidated Loss

Bharat Parenterals Ltd (BPL) reported a 19.8% increase in standalone revenue from operations in FY25, reaching X318.7 crores. The growth was driven by expanding therapeutic offerings and increasing penetration in semi-regulated international markets. However, on a consolidated basis, BPL reported a loss of X43.7 crores due to increased operating expenses, primarily attributed to Innoxel Lifesciences' full-year operations and Varenyam Healthcare's 5-month consolidation. Gross profit rose from X107.5 crores in FY24 to X166.8 crores in FY25, indicating the strength of the core business. Innoxel Lifesciences, BPL’s subsidiary, continued to advance its pipeline of complex and specialty injectable products for regulated markets, with over 20 molecules and plans to add more in the next 2-3 years.